FindTrial
Sign In

Role of Myo-inositol and D-chiro-inositol on Oocyte Quality

A Prospective, Randomized, Double Blind, Study on the Clinical Efficacy Myo-inositol Versus D-chiro-inositol in Women Undergoing in Vitro Fertilization Embryo Transfer.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01338844
Enrollment
Unknown
Registered
2011-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2011-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Poor oocyte quality, IVF failure

Brief summary

Controlled ovarian hyperstimulation with gonadotropins is an integral part of the various stimulation protocols for patients undergoing in-vitro fertilization (IVF) and other Assisted Reproductive Technologies (ART) such as intracytoplasmic sperm injection (ICSI). The hormonal control of multiple follicular growth and maturation is a critical part of ART procedures since it maximizes the yield of embryos to be transferred, thus increasing the cumulative pregnancy rate. Recent studies have shown the efficacy of myo-inositol (MI) supplementation as a simple and highly effective treatment in order to improve oocyte quality in patients undergoing IVF. Indeed, it was previously shown that MI follicular fluid (FF) concentration is a reliable predictor of oocyte quality. High MI concentration in the FF directly correlates with high oocyte and embryo quality. Another stereoisomer of Inositol was successfully used into clinical practice D-chiro-inositol (DCI). In particular, DCI supplementation was used to restore ovulation in hyperglycemic PCOS patients. In the present study we aim to compare MI versus DCI supplementation on oocyte quality of women undergoing IVF-ET

Interventions

DIETARY_SUPPLEMENTMyo-inositol
DIETARY_SUPPLEMENTD-chito-Inositol

Sponsors

Research Center for Reproductive Medicine Villa Mafalda
CollaboratorUNKNOWN
San Raffaele University Hospital, Italy
CollaboratorOTHER
AGUNCO Obstetrics and Gynecology Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* women undergoing IVF treatments * Body mass index \<28 * FSH \<10IU/L * Normal uterine cavity, anatomy and functions

Exclusion criteria

* PCOS * Stage III or IV endometriosis * Premature ovarian failure * Poor responder

Design outcomes

Primary

MeasureTime frame
number of morphologically mature oocytes—
Total international units (IU) of recombinant FSH administrated—
number of grade 1 embryos—

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026